Orbimed Advisors Llc - Jun 27, 2025 Form 4 Insider Report for Corvus Pharmaceuticals, Inc. (CRVS)

Signature
/s/ Carl L. Gordon, Member of OrbiMed Advisors LLC
Stock symbol
CRVS
Transactions as of
Jun 27, 2025
Transactions value $
$0
Form type
4
Date filed
7/1/2025, 09:23 PM
Previous filing
Jun 26, 2025
Next filing
Jul 30, 2025

Reporting Owners (2)

Name Relationship Address Signature Signature date CIK
ORBIMED ADVISORS LLC Director, 10%+ Owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK /s/ Carl L. Gordon, Member of OrbiMed Advisors LLC 2025-07-01 0001055951
OrbiMed Capital GP V LLC Director, 10%+ Owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK /s/ Carl L. Gordon, Member of OrbiMed Capital GP VI LLC 2025-07-01 0001615374

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CRVS Common Stock Exercise of in-the-money or at-the-money derivative security $4.89M +1.4M +20.13% $3.50 8.34M Jun 27, 2025 See Footnotes F2, F3
transaction CRVS Common Stock Sale -$4.89M -1.18M -14.1% $4.16 7.17M Jun 27, 2025 See Footnotes F1, F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CRVS Common Warrants (right to buy) Exercise of in-the-money or at-the-money derivative security $0 -1.4M -100% $0.00 0 Jun 27, 2025 Common Stock 1.4M $3.50 See Footnotes F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On June 27, 2025, OrbiMed Private Investments V, LP ("OPI V") exercised common warrants ("Warrants") to purchase 1,397,684 shares of the Issuer's Common Stock for $3.50 per share. OPI V paid the exercise price on a cashless basis, resulting in the Issuer withholding 1,176,332 of the Warrant shares to pay the exercise price and issuing to OPI V the remaining 221,352 shares.
F2 These securities are held of record by OPI V. OrbiMed Capital GP V LLC ("GP V") is the general partner of OPI V, and OrbiMed Advisors LLC ("OrbiMed Advisors"), a registered investment adviser under the Investment Advisors Act of 1940, as amended, is the managing member of GP V. By virtue of such relationships, GP V and OrbiMed Advisors may be deemed to have voting and investment power with respect to the securities held by OPI V noted above and as a result may be deemed to beneficially own such securities for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). OrbiMed Advisors exercises this investment and voting power through a management committee comprised of Carl L. Gordon, Sven H. Borho, and W. Carter Neild, each of whom disclaims beneficial ownership of the shares held by OPI V.
F3 This report on Form 4 is jointly filed by OrbiMed Advisors and GP V. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1943, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. OrbiMed Advisors and GP V have designated a representative, Peter A. Thompson, a member of OrbiMed Advisors, to serve on the Issuer's board of directors. This report shall not be deemed an admission that any of the Reporting Persons is a beneficial owner of such securities for purposes of Section 16 of the Exchange Act, or for any other purpose.